Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26

Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – February 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 26, 2026. Title:Mdxhealth Presents Fourth Quarter and Full Year 2025 Financial Results andCorporate Update Conference Call and WebcastDate:February 26, 2026Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Int’l: 1-412-317-5180Belgium: 0800 38 961United Kingdom: 0800 279 9489Conference ID:        10206764Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1753070&tp_key=27bce7d4de The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website. About Mdxhealth Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation), exosomal and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Waltham, Massachusetts and Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth. For more information:[email protected] LifeSci Advisors (IR & PR)John FrauncesManaging DirectorTel: +1 917 355 [email protected]
Attachment

mdx